Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Jak2 is involved in c-Myc induction by Bcr-Abl

Abstract

We have previously shown that the Jak2 tyrosine kinase is activated in Bcr-Abl positive cell lines and blood cells from CML blast crisis patients by tyrosine phosphorylation. We are searching for downstream targets of Jak2 in Bcr-Abl positive cells. It is known that c-Myc expression is required for the oncogenic effects of Bcr-Abl, and that over-expression of c-Myc complements the transformation defect of the Bcr-Abl SH2 deletion mutant. Moreover, the Bcr-Abl SH2 deletion mutant and an Abl C-terminal deletion mutant are deficient in activating c-Myc expression. Since the Jak2 binds to the C-terminal domain of Bcr-Abl and optimal Jak2 activation requires the SH2 domain, we tested whether Jak2 was involved in c-Myc protein induction by Bcr-Abl. We treated the 32Dp210 Bcr-Abl cells with the Jak2 specific tyrosine kinase inhibitor, AG490, and found that this drug, like the Abl tyrosine kinase inhibitor STI-571, inhibited c-Myc protein induction by Bcr-Abl. Treatment of 32Dp210 Bcr-Abl cells with AG490 also inhibited c-MYC RNA expression. It is also known that c-Myc protein is a labile protein that is increased in amounts in response to various growth factors by a mechanism not involving new Myc protein formation. Treatment of 32Dp210 Bcr-Abl cells with both the proteasome inhibitor MG132 and AG490 blocked the reduction of the c-Myc protein observed by AG490 alone. An adaptor protein SH2-Bβ is involved in the enhancement of the tyrosine kinase activity of Jak2 following ligand/receptor interaction. In this regard we showed that the Jak2/Bcr-Abl complex contains SH2-Bβ. Expression of the SH2-Bβ R555E mutant in 32Dp210 Bcr-Abl cells reduced c-Myc expression about 40% compared to a vector control. Interestingly, we found the reduction of the c-Myc protein in several clones of dominant-negative (DN) Jak2 expressing K562 cells correlated very well with the reduction of tumor growth of these cells in nude mice as compared to vector transfected K562 cells. Both STI-571 and AG490 also induced apoptosis in 32Dp210 cells. Of interest, IL-3 containing medium reversed the STI-571 induced apoptosis of 32Dp210 cells but did not reverse the induction of apoptosis by AG490, which strongly supports the specificity of the inhibitory effects of AG490 on the Jak2 tyrosine kinase. In summary, our findings indicate that Jak2 mediates the increase in c-Myc expression that is induced by Bcr-Abl. Our results indicate that activated Jak2 not only mediates an increase of c-MYC RNA expression but also interferes with proteasome-dependent degradation of c-Myc protein.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL . 1994 Science 264: 424–426

  • Besancon F, Afti A, Gespach C, Cayre YE, Bourgeade M-F . 1998 Proc. Natl. Acad. Sci. USA 95: 8081–8086

  • Carlesso N, Frank DA, Griffin JD . 1995 J. Exp. Med. 183: 811–820

  • Chai SK, Nichols GL, Rothman PB . 1997 J. Immunol. 159: 4720–4728

  • Chaturvedi P, Sharma S, Reddy EP . 1997 Mol. Cell. Biol. 17: 3295–3304

  • Ciechanover A, DiGiuseppe JA, Bercovich B, Orian A, Richter JD, Schwartz AI, Brodeur GM . 1991 Proc. Natl. Acad. Sci. USA 88: 139–143

  • Danial NN, Losman JA, Lu T, Yip N, Krishmnan K, Krolewski J, Goff SP, Wang JYJ, Rothman PB . 1998 Mol. Cell. Biol. 18: 6795–6804

  • de Groot RP, Raaijmakers JAM, Lammers JWJ, Jove R, Koenderman L . 1999 Blood 94: 1108–1112

  • Deininger WM, Goldman JM, Melo JV . 2000 Blood 96: 3343–3356

  • Digicaylioglu M, Lipton SA . 2001 Nature 412: 641–647

  • Dijkers PF, van Dijk TB, de Groot RP, Raaijmakers JAM, Lammers JWJ, Koenderman L, Coffer PJ . 1999 Oncogene 18: 3334–3342

  • Flinn EM, Busch CMC, Wright APH . 1998 Mol. Cell. Biol. 18: 5961–5969

  • Gesbert F, Griffin JD . 2000 Blood 96: 2269–2276

  • Gross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C, Ciechanover A . 1998 Proc. Natl. Acad. Sci. USA 95: 8058–8063

  • Guo JQ, Hirsch-Ginsberg CF, Xian YM, Stass SA, Champlin RE, Giralt Sa, McCredie KB, Campbell ML, Arlinghaus RB . 1993 Hematol. Pathol. 7: 91–106

  • Hann SR, Eisenman RN . 1984 Mol. Cell. Biol. 4: 2486–2497

  • Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL . 2000 J. Exp. Med. 191: 977–984

  • Ilaria RL, Van Etten RA . 1996 J. Biol. Chem. 271: 31704–31710

  • Jones TR, Cole MD . 1987 Mol. Cell. Biol. 7: 4513–4521

  • Luscher B, Eisenman R . 1990 Genes Dev. 4: 2025–2035

  • La Rosa FA, Pierce JW, Sonenshein GE . 1994 Mol. Cell. Biol. 14: 1039–1044

  • Miyamoto N, Sugita K, Goi K, Inukai T, Lijima K, Tezuka T, Kojika S, Nakamura M, Kagami K, Nakazawa S . 2001 Leukemia 15: 1758–1768

  • Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A . 1996 EMBO J. 15: 2425–2433

  • Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T . 1999 J. Exp. Med. 189: 1229–1242

  • Okuda K, d'Andrea RA, Van Etten RA, Griffin JD . 1998 Blood 92: 3848–3856

  • Ramsay G, Stanton L, Schwab M, Littlewood T, Even G . 1986 Mol. Cell. Biol. 6: 4450–4457

  • Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin Jr AS . 1998 Genes Dev. 12: 968–981

  • Rui L, Carter-Su C . 1999 Proc. Natl. Acad. Sci. USA 96: 7172–7177

  • Rui I, Gunter DR, Herrington J, Carter-Su C . 2000 Mol. Cell. Biol. 20: 3168–3177

  • Salghetti SE, Kim SY, Tansey WP . 1999 EMBO J. 18: 717–726

  • Sambrook J, Fritch EF, Maniatias T . 1989 Molecular Cloning 2nd edn Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press

    Google Scholar 

  • Sawyers CL, Callahan W, Witte ON . 1992 Cell 70: 901–910

  • Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR . 2000 Genes Dev. 14: 2501–2514

  • Sherr CL . 1998 Genes Dev. 12: 3499–3511

  • Shui K, Halpern J, ten Hoeve J, Rao X, Sawyers CL . 1996 Oncogene 13: 247–254

  • Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD . 2000 Blood 95: 2118–2125

  • Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B . 1997 EMBO J. 16: 6151–6161

  • Socolovsky M, Fallon AEJ, Wang S, Brugnara C, Lodish HF . 1999 Cell 98: 181–191

  • Stewart MG, Litz-Jackson S, Burgess GS, Williamson EA, Leiboitz DS, Bosswell HS . 1995 Leukemia 9: 1499–1507

  • Takeshita T, Arita T, Higuchi M, Asao H, Endo K, Kuroda H, Tanaka N, Murata K, Ishii N, Sugamura K . 1997 Immunity 6: 449–457

  • Watanabe S, Itoh T, Arai K . 1996 J. Biol. Chem. 271: 12681–12686

  • Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB . 1996 Cancer Res. 56: 3426–3430

  • Xie S, Wang Y, Liu J, Sun T, Arlinghaus R . 2001 Oncogene 20: 6188–6195

  • Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitsky A, Kraker A, Krolewski JJ, Medveczky P, Jove R . 2000 J. Biol. Chem. 275: 24935–24944

Download references

Acknowledgements

These studies were supported by grants CA 49639 and CA 16672 from NIH. We thank Dr Christin Carter-Su (University of Michigan at Ann Arbor) for providing SH2-Bβ antibody and the SH2-Bβ constructs. We also thank Norvartis Pharmaceuticals for providing STI-571. We thank Dr Tomasz Skorskl (Temple University, Philadelphia, PA, USA) for providing 32D cells expressing Bcr-Abl and its mutants.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ralph B Arlinghaus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xie, S., Lin, H., Sun, T. et al. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21, 7137–7146 (2002). https://doi.org/10.1038/sj.onc.1205942

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205942

Keywords

This article is cited by

Search

Quick links